Printer Friendly

CYTODIAGNOSTICS ELECTS FORMER HOFFMANN-LAROCHE DIVISION PRESIDENT AND MERCK SENIOR VP TO BOARD OF DIRECTORS

 OKLAHOMA CITY, Dec. 8 /PRNewswire/ -- CytoDiagnostics, Inc., the nation's leading provider of diagnostic services for urologists, today announced that Herbert J. Conrad, formerly president of the Pharmaceutical Division of Hoffmann-LaRoche, Inc., and Louis M. Sherwood, M.D., senior vice president of Merck & Co.'s U.S. Human Health division, have joined the company's Board of Directors. Conrad has more than 30 years of pharmaceutical industry experience, while Dr. Sherwood has served more than 25 years in academic medicine and the pharmaceutical industry.
 "CytoDiagnostics has become the nation's leading provider of clinical diagnostic services for genito-urinary malignancies and complex diseases by providing urologists with in vitro diagnostic capabilities to detect, diagnose, and prognose disease. As part of our strategic plan to expand our products and services to address the entire clinical continuum of urological disease -- from inception through treatment -- we are expanding our medical and disease management expertise. We are very honored that two such distinguished industry leaders have joined us in this effort," said William A. Hagstrom, president and chief executive officer.
 Until his retirement in August 1993, Conrad was president of the Pharmaceuticals Division of Hoffmann-LaRoche. During that time, he also served as a corporate senior vice president and a member of the executive committee and board of directors of Hoffmann-LaRoche. Previously, he held several senior management positions of increasing responsibility in marketing, business and strategic planning, and public affairs at Hoffmann-LaRoche. During his career, Conrad has served on many pharmaceutical-related boards. Most recently, he was appointed to the boards of directors for Gensia Pharmaceuticals, Inc. and Theragen, Inc.
 Sherwood is senior vice president of U.S. Medical and Scientific Affairs at Merck & Co. Before joining the industry, he had a long and distinguished career in academic medicine, research and medical administration. Most recently, he served for seven years as Baumritter Professor and chairman of the Department of Medicine at Albert Einstein College of Medicine. He also was professor of biochemistry and physician in chief at Montefiore Medical Center. Prior to joining Einstein, he was chairman of medicine at the Michael Reese Medical Center and Professor of Medicine at the University of Chicago. Earlier, he served as chief of endocrinology at Beth Israel Hospital and associate professor of medicine at Harvard Medical School.
 CytoDiagnostics, Inc., headquartered in Oklahoma, currently provides office-based urologists in the United States with oncology diagnostic testing services and pathology consultation services for the detection and management of genitourinary cancers and other complex urological diseases. The company is developing and commercializing a new generation of products and services which apply advances in molecular biology to the detection, monitoring and clinical management of cancers and other complex diseases treated by urologists.
 -0- 12/8/93
 /CONTACT: Socrates Choumbakos, chief financial officer of CytoDiagnostics, 405-848-4100; or Marcia A. Kean, executive vp of Feinstein Partners, 617-577-8110, for CytoDiagnostics/


CO: CytoDiagnostics, Inc.; Hoffman-Laroche, Inc.; Merck & Co.; Gensia
 Pharmaceuticals, Inc.; Theragen Inc. ST: Oklahoma IN: MTC SU: PER


JL -- NE003 -- 1746 12/08/93 12:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 8, 1993
Words:496
Previous Article:CARTER HAWLEY HALE BOARD AUTHORIZES PURSUIT OF FINANCING ALTERNATIVES
Next Article:GREEN MOUNTAIN COFFEE GOES MOBIL
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters